Abstract
The JmjC histone lysyl demethylases (KDMs) play important roles in modulating histone methylation states and have the potential to be regulated by oxygen availability. Lys241 of the KDM4 subfamily is proposed to be important in oxygen binding by KDM4A. We report evidence that, although Lys241 is unlikely to be directly involved in oxygen binding, it has an important role in coupling 2‐oxoglutarate cosubstrate oxidation with lysine demethylase activity. The results suggest that compounds promoting the uncoupling of substrate oxidation are of interest as JmjC‐KDM inhibitors.
Keywords: epigenetics, histone demethylase, methyllysine, oxygen sensing, transcription
Histone lysyl demethylases (KDMs) regulate gene transcription by catalysing the demethylation of methylated lysine residues on the N‐terminal tails of histones.1 Although the first KDMs to be identified, KDM1A/B, are amine oxidases,2 the majority of KDMs, that is, the human KDM2–7 subfamilies, are Jumonji‐C (JmjC) domain‐containing 2‐oxoglutarate (2OG) and iron(II)‐dependent dioxygenases (JmjC‐KDMs).3 JmjC‐KDMs couple the hydroxylation of methyllysine residues to the oxidative decarboxylation of 2OG, producing succinate and CO2; the resultant hydroxylated lysyl N‐methyl group is an unstable hemiaminal that fragments to give the demethylated lysine and formaldehyde (Scheme 1).4
Despite their structural and mechanistic similarities, the KDM2–7 enzymes have diverse sequences and methylation state specificities.5 KDM4A–E are perhaps the best studied of the JmjC‐KDMs, and accept mono‐, di‐ and trimethylated lysines as substrates; KDM4 catalysis has been observed at H3K9, H3K36 (KDM4A–C) and H1.4K26 (KDM4A–D).6 KDM4A/E have also been reported to catalyse the demethylation of N‐methylated arginines in the context of histone fragment peptides.7
Abnormal expression patterns of JmjC‐KDMs have been linked to multiple diseases and disorders including in autism,8 cardiac hypertrophy,9 mid‐line defects10 and several cancers.11 Consequently, modulating KDM activity is of medicinal interest. However, therapeutic targeting of KDMs is currently compromised by an incomplete understanding of their biochemical and physiological roles. For example, it is possible that KDM catalysis is regulated by the availability of O2 within some cells, although evidence for the physiological relevance of such regulation is incomplete.12
X‐ray crystal structures of KDM4 enzymes in complex with substrate peptides have been reported and provided insights into mechanism and a basis for inhibition studies.1 An early crystallographic and mutagenesis study on KDM4A by Chen et al. identified a catalytically essential active‐site lysine residue (K241) that was proposed to regulate O2 binding (Scheme 1);13 hence K241 is potentially involved in regulating the O2 sensitivity of KDM4s. K241, which is conserved within the KDM4 subfamily but absent in other KDMs, is therefore an attractive target residue for KDM4‐selective inhibitors.
Here, we report biochemical studies assessing the role of K241 in KDM4A catalysis. The results reveal that the K241A KDM4A variant is capable of catalysing substrate‐uncoupled oxidative decarboxylation of 2OG at comparable efficiency to wild‐type KDM4A, thus implying a similarly efficient reaction with O2 (at least for uncoupled turnover). Demethylation of a trimethylated H3K9 peptide by K241A KDM4A was also observed, although the catalysis was markedly less efficient than for wild‐type KDM4A, and demethylation activity was not increased upon increasing the O2 concentration. Binding analyses by fluorescence polarisation indicate similar binding efficiencies of the histone substrate to both the WT enzyme and the K241A variant. Overall, the results imply that K241 is important in KDM4A catalysis; although it does have a role in coupling 2OG oxidation and demethylation, it is unlikely to be involved in regulating O2 binding.
Initially, we produced two recombinant variants of KDM4A (residues 1–359) in Escherichia coli BL21(DE3) cells; a truncated wild‐type sequence (KDM4A WT), or a variant with an alanine in place of Lys241 (K241A KDM4A). Studies were then carried out to evaluate the ability of the two KDM4A proteins to catalyse the demethylation of a histone peptide substrate. The two proteins (1 μm) were individually incubated with 2OG (100 μm, a concentration well above its WT K M value of 26±7 μm),12b ascorbate (100 μm), ferrous iron (10 μm) and a 15‐residue H3K9me3 peptide (100 μm, sequence: ARTKQTARKme3STGGKA) in HEPES buffer (50 mm, pH 7.5) at 37 °C; the extent of the reaction was determined by using MALDI‐TOF mass spectrometry after 40 min. Substantial demethylation of the H3K9me3 peptide was observed in the sample with WT KDM4A, resulting in formation of both di‐ and monomethylated products (H3K9me2 and H3K9me1 respectively, Figure 1 A). The K241A variant, however, manifested only minimal KDM activity; no H3K9me1 or unmethylated peptide (H3K9me0) was evident, although low levels of H3K9me2 were observed (Figure 1 A). Demethylation was not increased by increasing the concentration of 2OG to 2 mm (Figures S1 and S2 in the Supporting Information). These findings suggest that K241 is required for efficient KDM activity, thus supporting previous work that also employed MS.13 Minimal K241A KDM4A‐catalysed demethylation activity was observed with other histone fragment peptides reported to be KDM4A substrates (Figure 1 B).
Given the role of K241 in O2 binding/recruitment proposed by Chen et al.,13 we postulated that the lack of KDM activity might be due to reduced binding of O2. 1H NMR analyses were therefore carried out to assess the ability of the WT and K241A KDM4A to catalyse substrate‐uncoupled turnover of 2OG to succinate, a process that requires O2 binding. Samples containing either WT or K241A (20.5 μm), an excess of 2OG (2 mm), ascorbate (1 mm), and ferrous iron (100 μm) in ammonium formate buffer (50 mm, pH 7.5) were subjected to 1H NMR analysis at 1.5 min intervals over a 30‐min reaction. With both WT and K241A KDM4A, the triplet 1H resonance at δ H=2.4 ppm (corresponding to 2OG) decreased in intensity during the analysis, while a new singlet 1H resonance at δ H=2.3 ppm, corresponding to succinate emerged (Figures 1 C and S3). The initial succinate formation rates were near identical with both enzymes (WT=1.35 μm min−1, K241A=1.55 μm min−1, Figure 1 C, note: 2OG turnover was too slow for accurate determination of the Michaelis–Menten kinetic parameters). Uncoupled 2OG turnover by the WT and K241A enzymes was inhibited by the 2OG competitor N‐oxalylglycine; interestingly, inhibition was more pronounced with the KDM4‐selective inhibitor JIB‐04 (Figures S4 and S5),14 which is proposed to interact with K241 in the KDM4A active site (inferred from modelling studies).15 Results from NMR binding experiments support preferential binding of JIB‐04 to the K241A variant over the WT enzyme (provisional K D(JIB‐04)=22±5 and 7±2 μm for WT and K241A, respectively, Figures 1 D and S6), thus implying no/suboptimal interactions between JIB‐04 and K241. Experiments were then conducted in the presence of a histone H3 eight‐residue fragment peptide containing N ϵ‐trimethyllysine at position 9 (H3K9me3, sequence: ARKme3STGGK). Initial succinate formation rates were markedly increased for both the WT and K241A enzymes; this implied binding of the histone fragment, which is reported to stimulate succinate formation by KDM4,16 and potentially demethylation. The 1H resonances corresponding to lysyl methyl groups were obscured by residual glycerol and HEPES from the enzyme stocks; this hindered the detection of KDM activity. Stimulation of succinate formation was greater for WT than for K241A KDM4A.
MS studies were then carried out to investigate whether demethylation by K241A KDM4A is stimulated by increasing the O2 concentration. KDM assays (using the same final concentrations of components as above) were carried out with the use of a Mass Flow Controller (Brooks Instruments) to equilibrate the reactions at either 20 or 80 % O2, as described;12b reactions were left for 10 min before quenching (with methanol) and MALDI‐TOF MS analysis. As reported, the KDM activity of WT KDM4A increased with increasing O2 concentration (from 31 to 46 % demethylation, Figure 1 E).12b However, only trace demethylation (<5 %) was observed in the samples with K241A KDM4A at either 20 or 80 % oxygen (Figure 1 E); this indicated that oxygen binding/recruitment does not limiting the KDM activity of the K241A variant.
The crystal structures of KDM4A appear to show that K241 interacts with the H3 fragment peptide substrate (Scheme 1, inset);17 we therefore investigated whether the KDM activity of the K241A variant is limited by weakened substrate binding. The binding of WT and K241A KDM4A to a histone fragment peptide was evaluated in a fluorescence polarisation assay. A 15‐residue H3K9me3 peptide C‐terminally labelled with a fluorescein fluorophore, that is, ARTKQTARKme3STGGKA‐fluorescein, was found by MALDI‐TOF MS to be a WT KDM4A demethylation substrate (a mass shift of −14 Da was observed under standard conditions). The labelled substrate (20 nm) was incubated with the 2OG analogue N‐oxalylglycine (1 mm),18 NiCl2 (10 μm) and various concentrations of the WT and K241A enzymes (0–20 μm). The fluorescence emission spectra of the samples parallel and perpendicular to the excitation plane were then measured, and used to calculate the fluorescence polarisation at each enzyme concentration. The apparent binding constants for peptide binding were near identical for both enzymes (3.06±2.9 μm for WT KDM4A, and 4.54±2.1 μm for K241A KDM4A, respectively), thus indicating that mutation of the K241 residue to alanine does not alter the affinity of KDM4A for the peptide substrate (Figure 1 F).
The overall MS, NMR spectroscopy and fluorescence polarisation studies imply that K241 has a role in KDM4A catalysis. However, the observation that the K241A variant catalyses uncoupled succinate formation with comparable efficiency to the WT implies that the role(s) of K241 during catalysis do not involve (at least initial) binding of O2.13 Thus, the observed mixed‐mode inhibition14 of K241A by JIB‐04 probably does not reflect direct disruption of O2 binding. Succinate formation by the K241A variant is stimulated by a histone fragment peptide, and a fluorescently labelled histone peptide binds in a similarly tight manner to the WT and K241A KDM4A. Thus, K241 appears to have a role in coupling 2OG turnover to substrate oxidation. One possibility is that K241 helps to orientate the methylated lysyl side chain within the KDM4A active site, thereby ensuring efficient oxidation of a methyl C−H bond after succinate formation. K241 might also limit the access to the active site of water molecules that could quench the reactive iron(IV)‐oxo intermediate before methyl C−H bond oxidation can occur. Targeting K241 is of interest both with respect to developing classical tightly binding inhibitors and to developing inhibitors that decouple 2OG and substrate oxidation. Such inhibitors are of interest because uncoupling could cause inactivation; in the absence of “prime” substrate, self‐oxidation of 2OG oxygenases can occur, either directly or through the production of reactive oxygen species.19 Therefore, molecules that bind and induce self‐oxidation before dissociating, for example, K241 binders, have the potential to be catalytic inactivators.
Conflict of interest
The authors declare no conflict of interest.
Supporting information
Acknowledgements
R.L.H., E.F. and A.K. acknowledge support from the British Heart Foundation Centre for Research Excellence, Oxford (RE/13/1/30181). This work was also funded by Cancer Research UK (C8717/A18245), the Wellcome Trust (091857/7/10/7) and the Biotechnology and Biological Sciences Research Council (BB/E527620/1). R.J.H. acknowledges a William R. Miller Junior Research Fellowship from St. Edmund Hall, Oxford. M.I.A. acknowledges a Junior Research Fellowship from Kellogg College, Oxford. We also thank David Ivison and Nathan Rose for help with the mutagenesis.
R. L. Hancock, M. I. Abboud, T. J. Smart, E. Flashman, A. Kawamura, C. J. Schofield, R. J. Hopkinson, ChemBioChem 2018, 19, 917.
Contributor Information
Prof. Christopher J. Schofield, Email: christopher.schofield@chem.ox.ac.uk.
Dr. Richard J. Hopkinson, Email: richard.hopkinson@leicester.ac.uk.
References
- 1. Cheng X., Trievel R. C. in 2-Oxoglutarate-Dependent Oxygenases, The Royal Society of Chemistry, 2015, pp. 210–245. [Google Scholar]
- 2.
- 2a. Shi Y., Lan F., Matson C., Mulligan P., Whetstine J. R., Cole P. A., Casero R. A., Shi Y., Cell 2004, 119, 941–953; [DOI] [PubMed] [Google Scholar]
- 2b. Ciccone D. N., Su H., Hevi S., Gay F., Lei H., Bajko J., Xu G., Li E., Chen T., Nature 2009, 461, 415–418. [DOI] [PubMed] [Google Scholar]
- 3.
- 3a. Tsukada Y., Fang J., Erdjument-Bromage H., Warren M. E., Borchers C. H., Tempst P., Zhang Y., Nature 2006, 439, 811–816; [DOI] [PubMed] [Google Scholar]
- 3b. Whetstine J. R., Nottke A., Lan F., Huarte M., Smolikov S., Chen Z., Spooner E., Li E., Zhang G., Colaiacovo M., Shi Y., Cell 2006, 125, 467–481; [DOI] [PubMed] [Google Scholar]
- 3c. Klose R. J., Yamane K., Bae Y., Zhang D., Erdjument-Bromage H., Tempst P., Wong J., Zhang Y., Nature 2006, 442, 312–316; [DOI] [PubMed] [Google Scholar]
- 3d. Yamane K., Toumazou C., Tsukada Y., Erdjument-Bromage H., Tempst P., Wong J., Zhang Y., Cell 2006, 125, 483–495; [DOI] [PubMed] [Google Scholar]
- 3e. Klose R. J., Yan Q., Tothova Z., Yamane K., Erdjument-Bromage H., Tempst P., Gilliland D. G., Zhang Y., W. G. Kaelin, Jr. , Cell 2007, 128, 889–900; [DOI] [PubMed] [Google Scholar]
- 3f. Feng W., Yonezawa M., Jung Y., Jenuwein T., Grummt I., Nat. Struct. Mol. Biol. 2010, 17, 445–450; [DOI] [PubMed] [Google Scholar]
- 3g. Loenarz C., Ge W., Coleman M. L., Rose N. R., Cooper C. D., Klose R. J., Ratcliffe P. J., Schofield C. J., Hum. Mol. Genet. 2010, 19, 217–222. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Walport L. J., Hopkinson R. J., Schofield C. J., Curr. Opin. Chem. Biol. 2012, 16, 525–534. [DOI] [PubMed] [Google Scholar]
- 5. Kooistra S. M., Helin K., Nat. Rev. Mol. Cell Biol. 2012, 13, 297–311. [DOI] [PubMed] [Google Scholar]
- 6.
- 6a. Williams S. T., Walport L. J., Hopkinson R. J., Madden S. K., Chowdhury R., Schofield C. J., Kawamura A., Epigenetics 2014, 9, 1596–1603; [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6b. Trojer P., Zhang J., Yonezawa M., Schmidt A., Zheng H., Jenuwein T., Reinberg D., J. Biol. Chem. 2009, 284, 8395–8405. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Walport L. J., Hopkinson R. J., Chowdhury R., Schiller R., Ge W., Kawamura A., Schofield C. J., Nat. Commun. 2016, 7, 11974. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. LaSalle J. M., OA Autism 2013, 1, 14. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Zhang Q.-J., Chen H.-Z., Wang L., Liu D.-P., Hill J. A., Liu Z.-P., J. Clin. Invest. 2011, 121, 2447–2456. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.
- 10a. Tahiliani M., Mei P., Fang R., Leonor T., Rutenberg M., Shimizu F., Li J., Rao A., Shi Y., Nature 2007, 447, 601; [DOI] [PubMed] [Google Scholar]
- 10b. Qi H. H., Sarkissian M., Hu G.-Q., Wang Z., Bhattacharjee A., Gordon D. B., Gonzales M., Lan F., Ongusaha P. P., Huarte M., Yaghi N. K., Lim H., Garcia B. A., Brizuela L., Zhao K., Roberts T. M., Shi Y., Nature 2010, 466, 503–507. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Højfeldt J. W., Agger K., Helin K., Nat. Rev. Drug Discovery 2013, 12, 917–930. [DOI] [PubMed] [Google Scholar]
- 12.
- 12a. Sánchez-Fernández E. M., Tarhonskaya H., Al-Qahtani K., Hopkinson R. J., McCullagh J. S., Schofield C. J., Flashman E., Biochem. J. 2013, 449, 491–496; [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12b. Hancock R. L., Masson N., Dunne K., Flashman E., Kawamura A., ACS Chem. Biol. 2017, 12, 1011–1019. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Chen Z., Zang J., Kappler J., Hong X., Crawford F., Wang Q., Lan F., Jiang C., Whetstine J., Dai S., Hansen K., Shi Y., Zhang G., Proc. Natl. Acad. Sci. USA 2007, 104, 10818–10823. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Wang L., Chang J., Varghese D., Dellinger M., Kumar S., Best A. M., Ruiz J., Bruick R., Peña-Llopis S., Xu J., Babinski D. J., Frantz D. E., Brekken R. A., Quinn A. M., Simeonov A., Easmon J., Martinez E. D., Nat. Commun. 2013, 4, 2035. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Cascella B., Lee S. G., Singh S., Jez J. M., Mirica L. M., Chem. Commun. 2017, 53, 2174–2177. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.
- 16a. Hopkinson R. J., Hamed R. B., Rose N. R., Claridge T. D., Schofield C. J., ChemBioChem 2010, 11, 506–510; [DOI] [PubMed] [Google Scholar]
- 16b. Hopkinson R. J., Walport L. J., Münzel M., Rose N. R., Smart T. J., Kawamura A., Claridge T. D. W., Schofield C. J., Angew. Chem. Int. Ed. 2013, 52, 7709–7713; [DOI] [PMC free article] [PubMed] [Google Scholar]; Angew. Chem. 2013, 125, 7863–7867; [Google Scholar]
- 16c. Walport L. J., Hopkinson R. J., Vollmar M., Madden S. K., Gileadi C., Oppermann U., Schofield C. J., Johansson C., J. Biol. Chem. 2014, 289, 18302–18313. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Ng S. S., Kavanagh K. L., McDonough M. A., Butler D., Pilka E. S., Lienard B. M. R., Bray J. E., Savitsky P., Gileadi O., von Delft F., Rose N. R., Offer J., Scheinost J. C., Borowski T., Sundstrom M., Schofield C. J., Oppermann U., Nature 2007, 448, 87–91. [DOI] [PubMed] [Google Scholar]
- 18. Hopkinson R. J., Tumber A., Yapp C., Chowdhury R., Aik W., Che K. H., Li X. S., Kristensen J. B. L., King O. N. F., Chan M. C., Yeoh K. K., Choi H., Walport L. J., Thinnes C. C., Bush J. T., Lejeune C., Rydzik A. M., Rose N. R., Bagg E. A., McDonough M. A., Krojer T. J., Yue W. W., Ng S. S., Olsen L., Brennan P. E., Oppermann U., Müller S., Klose R. J., Ratcliffe P. J., Schofield C. J., Kawamura A., Chem. Sci. 2013, 4, 3110–3117. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Mantri M., Zhang Z., McDonough M. A., Schofield C. J., FEBS J. 2012, 279, 1563–1575. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.